Pulse Biosciences

Yahoo Finance • 4 days ago

Small-cap healthcare stocks with A+ grade EPS revisions ahead of earnings

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As Q1 2026 earnings season approaches, the healthcare sector enters reporting season as one of the market's primary... Full story

Yahoo Finance • 6 days ago

Pulse Begins Pivotal NANOPULSE-AF Trial After Strong 96% Procedural Success In Earlier Study

(RTTNews) - Pulse Biosciences Inc. (PLSE) has taken a major step forward in its atrial fibrillation program, enrolling the first patients in its pivotal U.S. Investigational Device Exemption (IDE) study, NANOPULSE-AF. The milestone follow... Full story

Yahoo Finance • 7 days ago

Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation

U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study HAYWARD, Calif., April 07, 2026--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using p... Full story

Yahoo Finance • 2 months ago

Pulse Biosciences GAAP EPS of -$0.26 beats by $0.05, revenue of $0.26M beats by $0.01M

* Pulse Biosciences press release [https://seekingalpha.com/pr/20388541-pulse-biosciences-schedules-fourth-quarter-and-full-year-2025-financial-results-conference] (PLSE [https://seekingalpha.com/symbol/PLSE]): Q4 GAAP EPS of -$0.26 beat... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Rise in Afternoon Trading

Health care stocks rose Friday afternoon, with the NYSE Health Care Index increasing 1.3% and the St PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium

nPulse Cardiac Catheter for AF ablation to be highlighted in late-breaking clinical science session and in a live case transmission HAYWARD, Calif., February 03, 2026--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company lev... Full story

Yahoo Finance • 3 months ago

Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

HAYWARD, Calif., December 29, 2025--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today... Full story

Yahoo Finance • 5 months ago

Pulse Biosciences is Now Oversold (PLSE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 8 months ago

Pulse Biosciences reports success in thyroid nodule treatment study

HAYWARD, Calif. - Pulse Biosciences, Inc. (NASDAQ:PLSE), a $1.11 billion market cap medical technology company with strong liquidity metrics, announced that a first-in-human clinical feasibility study has demonstrated the effectiveness of... Full story

Yahoo Finance • 8 months ago

Pulse Biosciences outlines initial percutaneous electrode revenue and IDE milestones while expanding nsPFA clinical programs

Earnings Call Insights: Pulse Biosciences (PLSE) Q2 2025 MANAGEMENT VIEW * Paul Arthur LaViolette, President and CEO, described the ongoing expansion across three market development programs, emphasizing the clinical and commercial pro... Full story

Yahoo Finance • 2 years ago

Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

HAYWARD, Calif., November 15, 2023--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment o... Full story

Yahoo Finance • 2 years ago

UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call

Pulse Biosciences will host a conference call at 9:00 am PT / 12:00 pm ET on Monday, November 13, 2023 HAYWARD, Calif., November 10, 2023--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, "the Company"), a company primarily focused... Full story

Yahoo Finance • 3 years ago

Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting

HAYWARD, Calif., May 18, 2023--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today anno... Full story

Yahoo Finance • 3 years ago

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2023 Earnings Call Transcript

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2023 Earnings Call Transcript May 11, 2023 Pulse Biosciences, Inc. misses on earnings expectations. Reported EPS is $-0.23 EPS, expectations were $-0.22. Operator: Good afternoon, ladies and gentl... Full story

Yahoo Finance • 3 years ago

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2022 Earnings Call Transcript

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2022 Earnings Call Transcript March 30, 2023 Operator: Ladies and gentlemen, greetings, and welcome to the Pulse Biosciences' Fourth Quarter 2022 Earnings Conference Call. At this time all particip... Full story

Yahoo Finance • 4 years ago

Stock rebound uncertain for U.S. biotechs as risks multiply for investors

U.S. biotechs and other health care stocks accounted for about 11% of all losses in U.S. equity values during the five-month period analyzed by The Business Journals.... Full story

Yahoo Finance • 4 years ago

Pulse Biosciences Reports First Quarter 2022 Financial Results

HAYWARD, Calif., May 11, 2022--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced financial... Full story

Yahoo Finance • 4 years ago

PLSE DEADLINE ALERT: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Pulse Biosciences, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Monday Deadline in Securities Class Action – PLSE

NEW YORK, April 16, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pulse Biosciences, Inc. (NASDAQ: PLSE) between January 12, 2021 and February 7, 2022, inclusive... Full story

Yahoo Finance • 4 years ago

DEADLINE ALERT for SPWR, PLSE, BFLY, GWGH: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

BENSALEM, Pa., April 15, 2022 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story

Yahoo Finance • 4 years ago

SPWR, PLSE & MP Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Upcoming Class Action Deadlines and to Contact the Firm

NEW YORK, April 12, 2022 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy o... Full story